Ipsen
Ipsen S.A. is a French biopharmaceutical company focused on the innovation and commercialization of specialty medicines worldwide. The company concentrates its pipeline and commercial operations across three core therapeutic areas: Oncology, Rare Diseases, and Neuroscience. Key flagship products encompass Somatuline for neuroendocrine tumors, Dysport for spasticity and aesthetic treatments, and Cabometyx for renal cell carcinoma. Primary revenue drivers are global prescription sales of specialty pharmaceuticals to health systems, specialty pharmacies, and wholesalers. Ipsen holds a major international market position in targeted specialty biopharmaceuticals. The company is headquartered in Boulogne-Billancourt, France, and its shares are listed on Euronext Paris.
42 of the funds FundTelligence covers report a position in Ipsen.
- Legal name
- Ipsen S.A.
- Sector
- Health Care
- Country
- France
- Funds holding it
- 42
Funds holding Ipsen
- Storebrand Global Value — Storebrand · 1.17 % (full portfolio disclosed, October 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.63 % (full portfolio disclosed, October 2026)
- JPM Euroland Equity Fund — JPM · 0.31 % (full portfolio disclosed, June 2026)
- Handelsbanken Infrastruktur och Beredskap — Handelsbanken · 0.3 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI Europe Health Care Sector UCITS ETF — BlackRock · 0.3 % (full portfolio disclosed, October 2026)
- Nordea European Enhanced — Nordea Funds · 0.28 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI World Health Care Sector ESG UCITS ETF — BlackRock · 0.28 % (full portfolio disclosed, October 2026)
- Nordea Europe Enhanced — Nordea Funds · 0.28 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 42 funds holding it.